Top 5 Drug Type | Count |
---|---|
siRNA | 17 |
Drug conjugates | 1 |
Prophylactic vaccine | 1 |
Biological products | 1 |
mRNA vaccine | 1 |
Top 5 Target | Count |
---|---|
COX-2 x TGF-β1 | 2 |
APOC3(Apolipoprotein C-III) | 1 |
COX-2(Cyclooxygenase-2) | 1 |
TTR(Transthyretin) | 1 |
C5 x CFB | 1 |
Target |
Mechanism COX-2 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism COX-2 inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism RNA interference |
Active Org. |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jun 2023 |
Sponsor / Collaborator |
Start Date16 May 2023 |
Sponsor / Collaborator |
Start Date01 Aug 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Pixofisiran/Lixadesiran ( COX-2 x TGF-β1 ) | Cutaneous Squamous Cell Carcinoma More | Phase 2 |
FXI-GalNAc-siRNA | - | Phase 1 |
STP-707 ( COX-2 x TGF-β1 ) | Liver Cirrhosis More | Phase 1 |
STP-908 ( SARS-CoV-2 N protein x SARS-CoV-2 ORF1Ab ) | COVID-19 More | IND Application |
RV-1730 ( SARS-CoV-2 antigen ) | COVID-19 More | IND Application |